Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide.

× No keyword cloud information.

11 in total

1. Treatment and management of neuromuscular channelopathies.

Authors: Lydia Sharp; Jaya R Trivedi
Journal: Curr Treat Options Neurol Date: 2014-10 Impact factor: 3.598

2. SCN4A pore mutation pathogenetically contributes to autosomal dominant essential tremor and may increase susceptibility to epilepsy.

Authors: Alberto Bergareche; Marcin Bednarz; Elena Sánchez; Catharine E Krebs; Javier Ruiz-Martinez; Patricia De La Riva; Vladimir Makarov; Ana Gorostidi; Karin Jurkat-Rott; Jose Felix Marti-Masso; Coro Paisán-Ruiz
Journal: Hum Mol Genet Date: 2015-10-01 Impact factor: 6.150

3. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype.

Authors: E Matthews; S Portaro; Q Ke; R Sud; A Haworth; M B Davis; R C Griggs; M G Hanna
Journal: Neurology Date: 2011-11-16 Impact factor: 9.910

Review 4. Hypokalemic periodic paralysis: a model for a clinical and research approach to a rare disorder.

Authors: Bertrand Fontaine; Emmanuel Fournier; Damien Sternberg; Savine Vicart; Nacira Tabti
Journal: Neurotherapeutics Date: 2007-04 Impact factor: 7.620

Review 5. Challenges in the design and conduct of therapeutic trials in channel disorders.

Authors: Shannon L Venance; Barbara E Herr; Robert C Griggs
Journal: Neurotherapeutics Date: 2007-04 Impact factor: 7.620

6. Cannabidiol inhibits the skeletal muscle Nav1.4 by blocking its pore and by altering membrane elasticity.

Authors: Koushik Choudhury; Tagore S Bandaru; Mohamed A Fouda; Kaveh Rayani; Mohammad-Reza Ghovanloo; Radda Rusinova; Tejas Phaterpekar; Karen Nelkenbrecher; Abeline R Watkins; Damon Poburko; Jenifer Thewalt; Olaf S Andersen; Lucie Delemotte; Samuel J Goodchild; Peter C Ruben
Journal: J Gen Physiol Date: 2021-05-03 Impact factor: 4.086

SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide.

1. Treatment and management of neuromuscular channelopathies.

2. SCN4A pore mutation pathogenetically contributes to autosomal dominant essential tremor and may increase susceptibility to epilepsy.

3. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype.

Review 4. Hypokalemic periodic paralysis: a model for a clinical and research approach to a rare disorder.

Review 5. Challenges in the design and conduct of therapeutic trials in channel disorders.

6. Cannabidiol inhibits the skeletal muscle Nav1.4 by blocking its pore and by altering membrane elasticity.

7. Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

8. Skeletal muscle na channel disorders.

9. Hypokalemic periodic paralysis; two different genes responsible for similar clinical manifestations.

10. The genotype and clinical phenotype of Korean patients with familial hypokalemic periodic paralysis.